Study wrapper · #797
Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers.
Editor's note
This retrospective cohort compared 142 adults with type 1 diabetes and obesity started on tirzepatide against 50 matched controls over 12 months, notable because tirzepatide is not indicated in type 1 diabetes. Researchers reported significant reductions versus controls in HbA1c (-6.5 mmol/mol, about 0.6%), weight (-13.4 kg) and total daily insulin (-29.9 units), plus improvements in blood pressure and lipids, with 89.4% still on treatment at one year and no between-group difference in severe hypoglycaemia, ketoacidosis or hospitalisation. As a single, modest-sized, retrospective observational study it cannot exclude confounding, and ketoacidosis risk in type 1 diabetes warrants ongoing caution despite the reassuring signal here. The authors rightly call for randomised trials. Read it as promising real-world, hypothesis-generating data in an off-label, high-risk population, not established practice.
Plain-language abstract
This study looked at 142 adults who have type 1 diabetes along with obesity and were started on tirzepatide, comparing them with 50 similar people who were not. This is unusual because tirzepatide is normally used for type 2 diabetes, not type 1. Over a year, the tirzepatide group had meaningfully lower long-term blood sugar, lost about 13 kg, and needed substantially less insulin, along with better blood pressure and cholesterol. Nearly 90% were still taking it after a year, and there was no increase in dangerous low blood sugar, diabetic ketoacidosis, or hospital stays compared with the others. Because this used past records rather than random assignment, other differences between the groups could have affected results, and ketoacidosis remains a concern to watch in type 1 diabetes. The authors say proper randomised trials are needed before this becomes standard.